Nicole Gastineau Campos, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 46 | 2024 | 2020 | 6.930 |
Why?
|
Papillomavirus Infections | 40 | 2024 | 1613 | 6.500 |
Why?
|
Uterine Cervical Dysplasia | 9 | 2022 | 384 | 3.570 |
Why?
|
Papillomavirus Vaccines | 18 | 2024 | 496 | 3.240 |
Why?
|
Early Detection of Cancer | 26 | 2024 | 3201 | 3.180 |
Why?
|
Cost-Benefit Analysis | 24 | 2021 | 5493 | 2.020 |
Why?
|
Papillomaviridae | 14 | 2023 | 1119 | 2.000 |
Why?
|
Mass Screening | 21 | 2023 | 5429 | 1.850 |
Why?
|
Alphapapillomavirus | 7 | 2022 | 218 | 1.750 |
Why?
|
Colposcopy | 9 | 2022 | 150 | 1.130 |
Why?
|
Models, Theoretical | 10 | 2019 | 3575 | 1.100 |
Why?
|
Health Resources | 5 | 2024 | 935 | 1.060 |
Why?
|
Vaccination | 12 | 2024 | 3384 | 0.870 |
Why?
|
Human papillomavirus 18 | 9 | 2024 | 125 | 0.850 |
Why?
|
Human papillomavirus 16 | 10 | 2024 | 267 | 0.830 |
Why?
|
Monte Carlo Method | 7 | 2021 | 1258 | 0.710 |
Why?
|
Health Policy | 4 | 2019 | 2684 | 0.710 |
Why?
|
Developing Countries | 10 | 2020 | 2885 | 0.650 |
Why?
|
Specimen Handling | 3 | 2021 | 702 | 0.600 |
Why?
|
Models, Economic | 4 | 2021 | 716 | 0.600 |
Why?
|
Computer Simulation | 6 | 2021 | 6241 | 0.600 |
Why?
|
Vaginal Smears | 7 | 2021 | 499 | 0.570 |
Why?
|
DNA, Viral | 4 | 2020 | 2202 | 0.500 |
Why?
|
Medically Underserved Area | 1 | 2017 | 254 | 0.490 |
Why?
|
El Salvador | 3 | 2019 | 32 | 0.460 |
Why?
|
Bioethics | 2 | 2004 | 117 | 0.410 |
Why?
|
Uganda | 6 | 2019 | 1332 | 0.380 |
Why?
|
Choice Behavior | 1 | 2017 | 825 | 0.380 |
Why?
|
Selection Bias | 1 | 2011 | 359 | 0.340 |
Why?
|
Female | 53 | 2024 | 392705 | 0.330 |
Why?
|
Mass Vaccination | 2 | 2019 | 109 | 0.290 |
Why?
|
Models, Statistical | 3 | 2017 | 5079 | 0.270 |
Why?
|
Adult | 29 | 2024 | 221210 | 0.260 |
Why?
|
Humans | 56 | 2024 | 761596 | 0.230 |
Why?
|
Mississippi | 2 | 2021 | 95 | 0.230 |
Why?
|
Public Health | 1 | 2017 | 2669 | 0.230 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 662 | 0.220 |
Why?
|
Human Experimentation | 1 | 2004 | 123 | 0.210 |
Why?
|
Cryosurgery | 2 | 2018 | 474 | 0.210 |
Why?
|
Social Justice | 2 | 2004 | 478 | 0.200 |
Why?
|
Middle Aged | 20 | 2022 | 220921 | 0.200 |
Why?
|
Costa Rica | 3 | 2023 | 180 | 0.190 |
Why?
|
Resource Allocation | 1 | 2004 | 350 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4024 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 10212 | 0.180 |
Why?
|
Human Rights | 1 | 2004 | 309 | 0.180 |
Why?
|
Quality-Adjusted Life Years | 5 | 2019 | 1722 | 0.180 |
Why?
|
New Mexico | 2 | 2018 | 83 | 0.160 |
Why?
|
Hepatitis C, Chronic | 1 | 2007 | 1032 | 0.160 |
Why?
|
Young Adult | 9 | 2019 | 59260 | 0.150 |
Why?
|
Models, Biological | 1 | 2014 | 9469 | 0.150 |
Why?
|
Decision Making | 1 | 2011 | 3929 | 0.150 |
Why?
|
HIV Infections | 4 | 2022 | 17354 | 0.150 |
Why?
|
Nicaragua | 1 | 2017 | 29 | 0.150 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2023 | 491 | 0.140 |
Why?
|
Cost of Illness | 1 | 2007 | 1937 | 0.140 |
Why?
|
Immunization Schedule | 1 | 2018 | 227 | 0.140 |
Why?
|
Cancer Vaccines | 1 | 2023 | 1051 | 0.120 |
Why?
|
Women's Health | 2 | 2017 | 2065 | 0.120 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3358 | 0.120 |
Why?
|
Adolescent | 11 | 2024 | 88326 | 0.120 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 463 | 0.120 |
Why?
|
Antiviral Agents | 1 | 2007 | 3060 | 0.120 |
Why?
|
Incidence | 5 | 2023 | 21355 | 0.120 |
Why?
|
Risk Reduction Behavior | 2 | 2017 | 1112 | 0.110 |
Why?
|
South Africa | 1 | 2018 | 1843 | 0.110 |
Why?
|
Poverty | 1 | 2004 | 2697 | 0.100 |
Why?
|
Physical Examination | 1 | 2018 | 1255 | 0.100 |
Why?
|
Colorectal Neoplasms | 3 | 2023 | 6938 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2023 | 1853 | 0.100 |
Why?
|
India | 1 | 2018 | 2348 | 0.100 |
Why?
|
Africa, Eastern | 1 | 2011 | 76 | 0.100 |
Why?
|
Health Promotion | 1 | 2004 | 2214 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1386 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2021 | 2180 | 0.090 |
Why?
|
Patient Compliance | 1 | 2021 | 2690 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 610 | 0.090 |
Why?
|
Life Expectancy | 1 | 2017 | 1243 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.090 |
Why?
|
Time | 1 | 2011 | 546 | 0.090 |
Why?
|
Age Factors | 3 | 2019 | 18399 | 0.080 |
Why?
|
Income | 1 | 2017 | 1877 | 0.080 |
Why?
|
Social Class | 1 | 2017 | 2004 | 0.080 |
Why?
|
Health Services Accessibility | 2 | 2015 | 5440 | 0.080 |
Why?
|
Emigrants and Immigrants | 1 | 2015 | 543 | 0.080 |
Why?
|
Pregnancy | 3 | 2022 | 29890 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20100 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15733 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2508 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7828 | 0.070 |
Why?
|
Neoplasms | 3 | 2023 | 22173 | 0.070 |
Why?
|
Survival Analysis | 2 | 2011 | 10090 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2011 | 2358 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 4016 | 0.060 |
Why?
|
Ribavirin | 1 | 2007 | 395 | 0.060 |
Why?
|
Siberia | 1 | 2004 | 30 | 0.060 |
Why?
|
Urban Health | 1 | 2007 | 532 | 0.060 |
Why?
|
Breast Neoplasms | 3 | 2023 | 21019 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12723 | 0.060 |
Why?
|
United States | 7 | 2023 | 72340 | 0.060 |
Why?
|
Aged | 5 | 2022 | 169310 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2019 | 5337 | 0.060 |
Why?
|
Licensure | 1 | 2024 | 128 | 0.050 |
Why?
|
Markov Chains | 1 | 2007 | 966 | 0.050 |
Why?
|
Child | 6 | 2021 | 80158 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2007 | 921 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7391 | 0.050 |
Why?
|
Prisons | 1 | 2004 | 174 | 0.050 |
Why?
|
Research Subjects | 1 | 2004 | 249 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2011 | 1998 | 0.050 |
Why?
|
Time Factors | 3 | 2020 | 39969 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39106 | 0.050 |
Why?
|
Baltimore | 1 | 2021 | 231 | 0.050 |
Why?
|
Prospective Studies | 2 | 2022 | 54423 | 0.040 |
Why?
|
Cervix Uteri | 1 | 2023 | 570 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14665 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2019 | 80647 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2578 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13381 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1897 | 0.040 |
Why?
|
Recurrence | 1 | 2011 | 8466 | 0.040 |
Why?
|
Vagina | 1 | 2024 | 838 | 0.040 |
Why?
|
Geography | 1 | 2020 | 656 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8002 | 0.040 |
Why?
|
Goals | 1 | 2023 | 711 | 0.040 |
Why?
|
Developed Countries | 1 | 2020 | 449 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2007 | 6534 | 0.040 |
Why?
|
Standard of Care | 1 | 2020 | 551 | 0.030 |
Why?
|
Occult Blood | 1 | 2017 | 198 | 0.030 |
Why?
|
Sexual Partners | 1 | 2021 | 796 | 0.030 |
Why?
|
Cohort Studies | 2 | 2011 | 41495 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2022 | 1475 | 0.030 |
Why?
|
California | 1 | 2020 | 1430 | 0.030 |
Why?
|
Risk Assessment | 2 | 2020 | 23996 | 0.030 |
Why?
|
Mammography | 2 | 2017 | 2430 | 0.030 |
Why?
|
Self Care | 1 | 2020 | 796 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15266 | 0.030 |
Why?
|
Cuba | 1 | 2015 | 48 | 0.030 |
Why?
|
Publishing | 1 | 2022 | 833 | 0.030 |
Why?
|
Malaria | 1 | 2004 | 1227 | 0.030 |
Why?
|
Florida | 1 | 2015 | 431 | 0.030 |
Why?
|
Cross Protection | 1 | 2012 | 25 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2015 | 221 | 0.030 |
Why?
|
Haiti | 1 | 2015 | 550 | 0.030 |
Why?
|
Algorithms | 2 | 2024 | 14033 | 0.020 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1334 | 0.020 |
Why?
|
Tuberculosis | 1 | 2004 | 2017 | 0.020 |
Why?
|
Feces | 1 | 2017 | 1497 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 744 | 0.020 |
Why?
|
Kenya | 1 | 2012 | 758 | 0.020 |
Why?
|
Biomedical Research | 1 | 2004 | 3429 | 0.020 |
Why?
|
Research Design | 1 | 2024 | 6180 | 0.020 |
Why?
|
Male | 5 | 2023 | 360846 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2019 | 64685 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 12990 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2220 | 0.020 |
Why?
|
Health Behavior | 1 | 2015 | 2644 | 0.010 |
Why?
|
Health Care Costs | 1 | 2015 | 3242 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74213 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8225 | 0.010 |
Why?
|